Disseminated follicular eruption during therapy with the MEK inhibitor AZD6244

Journal of the American Academy of Dermatology

Volumn 64, Issue 2, 2011, Pages

  Querfeld, Christiane ^a   Duffy, Keith ^a   Magel, George ^b   Oble, Darryl ^a   Cohen, Ezra E W ^a   Shea, Christopher R ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; BENZOYL PEROXIDE; DOXYCYCLINE; GLUCOSAMINE; LEVOTHYROXINE; METOPROLOL; MULTIVITAMIN; SELUMETINIB;

AGED; ANOREXIA; CASE REPORT; COAGULASE NEGATIVE STAPHYLOCOCCUS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HISTOLOGY; HUMAN; HUMAN TISSUE; LETTER; MALASSEZIA; MALE; NAUSEA; PAPULE; PNEUMONIA; PRIORITY JOURNAL; PUSTULE; RASH; SKIN BIOPSY; THYROID CARCINOMA;

EID: 78751481518     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2009.06.070     Document Type: Article

References (8)

1. J.S. Sebolt-Leopold Advances in the development of cancer therapeutics directed against the RAS-mitogen-activated protein kinase pathway Clin Cancer Res 14 2008 3651 3656
2. T.C. Yeh, V. Marsh, B.A. Bernat, J. Ballard, H. Colwell, and R.J. Evans Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor Clin Cancer Res 13 2007 1576 1583
3. A.A. Adjei, R.B. Cohen, W. Franklin, C. Morris, D. Wilson, and J.R. Molina Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers J Clin Oncol 26 2008 2139 2146
4. T.J. Lynch Jr., E.S. Kim, B. Eaby, J. Garey, D.P. West, and M.E. Lacouture Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management Oncologist 12 2007 610 621
5. T. Yamazaki, H. Nakano, M. Hayakari, M. Tanaka, J. Mayama, and S. Tsuchida Differentiation induction of human keratinocytes by phosphatidylethanolamine-binding protein J Biol Chem 279 2004 32191 32195
6. J. Albanell, F. Rojo, S. Averbuch, A. Feyereislova, J.M. Mascaro, and R. Herbst Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition J Clin Oncol 20 2002 110 124
7. M.S. Cuetara, A. Aguilar, L. Martin, C. Aspiroz, and A. del Palacio Erlotinib associated with rosacea-like folliculitis and Malassezia sympodialis Br J Dermatol 155 2006 477 479
8. A.K. Gupta, R. Batra, R. Bluhm, T. Boekhout, and T.L. Dawson Jr. Skin diseases associated with Malassezia species J Am Acad Dermatol 51 2004 785 798